Abstract
The main cause of Addison’s disease is an autoimmune organ-specific destruction of the cells in the adrenal cortex by an autoreactive process of activated immune cells directed against the steroid-synthesising enzyme 21-hydroxylase. The diagnosis of Addison’s disease is suspected in a patient presenting with symptoms of fatigue, bodyweight loss, anorexia, salt craving, and signs of low blood pressure and hyperpigmentation of the skin. Laboratory findings include electrolyte disturbances, and typically an elevated serum potassium level and sometimes a low serum sodium level is found together with low plasma levels of basal and corticotropin-stimulated hydrocortisone (cortisol). An aetiological diagnosis can rapidly be made using commercially available assays demonstrating the presence of autoantibodies directed against 21-hydroxylase. Determination of 21-hydroxylase autoantibodies also permits early diagnosis before a complete adrenocortical destruction has occurred. Thus, a window of opportunity for an early immunomodulatory intervention therapy may exist. Patients presenting with an acute adrenocortical crisis should be treated with 100mg of hydrocortisone and saline intravenously without awaiting laboratory results. Maintenance therapy includes substitution of glucocorticoid and mineralocorticoid steroids, using divided and lower total dosages of glucocorticoids than previously used.
Similar content being viewed by others
References
Mosser J, Douar A-M, Sarde C-O, et al. Putative x-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature 1993; 361: 726–30
Miller WL. Molecular biology of steroid hormone synthesis. Endocr Rev 1988; 9: 295–318
Addison T. On the constitutional and local effects of disease of the suprarenal capsules. In: Highley D, editor. London: 1855
Nomura K, Demura H, Saruta T. Addison’s disease in Japan: characteristics and changes revealed in a nationwide survey. Intern Med 1994; 33: 602–6
Ofuji N, Yasuhara T, Murakami M, et al. A case of idiopathic Addison’s disease with chronic thyroiditis and ovarian dysfunction. Jap J Med 1977; 16: 124–9
Laureti S, Vecchi L, Santeusanio F, et al. Is the prevalence of Addison’s disease underestimated. J Clin Endocrinol Metab 1999; 84: 1762
Maclaren NK, Riley WJ. Inherited susceptibility to autoimmune Addison’s disease is linked to human leukocyte antigens-DR3 and/or DR4, except when associated with autoimmune polyglandular syndrome. J Clin Endocrinol Metab 1986; 62: 455–9
John ME, John MC, Boggaram V, et al. Transcriptional regulation of steroid hydroxylase genes by corticotropin. Proc Natl Acad Sci USA 1986; 83: 4715–9
Streeten DHP. Editorial: shortcomings in the low-dose (1μg) ACTH test for the diagnosis of ACTH deficiency states. J Clin Endocrinol Metab 1999; 84: 835–7
Clark PM, Neylon I, Raggatt PR, et al. Defining the normal cortisol response to the short Synacthen test: implications for the investigation of hypothalamic-pituitary disorders. Clin Endocrinol 1998; 49: 287–92
Winqvist O, Karlsson FA, Kämpe O. 21-Hydroxylase, a major autoantigen in idiopathic Addison’s disease. Lancet 1992; 339: 1559–62
Bednarek J, Furmaniak J, Wedlock N, et al. Steroid 21-hydroxylase is a major autoantigen involved in adult onset autoimmune Addison’s disease. FEBS Lett 1992; 309: 51–5
Uibo R, AAvik E, Peterson P, et al. Autoantibodies to cytochrome P450 enzymes P450scc, P450cl7 and P450c21 in autoimmune polyglandular disease types I and II and in isolated Addison’s disease. J Clin Endocrinol Metab 1994; 78: 323–8
Song Y-H, Connor EL, Muir A, et al. Autoantibody epitope mapping of the 21-hydroxylase antigen in autoimmune Addison’s disease. J Clin Endocrin Metab 1994; 78: 1108–12
Falorni A, Nikoshkov A, Laureti S, et al. High diagnostic accuracy for idiopathic Addison’s disease with a sensitive radiobinding assay for autoantibodies against recombinant human 21-hydroxylase. J Clin Endocrinol Metab 1995; 80: 2752–5
Laureti S, Bellis AD, Muccitelli V, et al. Levels of adrenocortical autoantibodies correlate with the degree of adrenal dysfunction in subjects with preclinical Addison’s disease. J Clin Endocrinol Metab 1998; 83: 3507–11
Peterson P, Salmi H, Hyoty H, et al. Steroid 21-hydroxylase autoantibodies in insulin-dependent diabetes mellitus. Childhood diabetes in Finland (DiMe) study group. Clin Immunol Immunopathol 1997; 82: 37–42
Yu L, Brewer K, Gates S, et al. DRB1*04 and DQ alleles: expression of 21-hydroxylase autoantibodies and risk of progression to Addison’s disease. J Clin Endocrinol Metab 1999; 84: 328–35
Boehm CD, Cutting G, Lachtermacher MB, et al. Accurate DNA-based diagnostic and carrier testing for x-linked adrenoleukodystrophy. Mol Genet Metab 1999; 66: 128–36
Orth DN, Kovacs WJ, Debold CR. The adrenal cortex. In: Wilson JD, Foster DW, editors. Williams textbook of endocrinology. 8th ed. Philadelphia: WB Saunders Company, 1992: 489–619
Salem M, Tainish RE, Bromberg J, et al. Perioperative glucocorticoid coverage. A reassessment 42 years after emergence of a problem. Ann Surg 1994; 219: 416–25
Howlett T. An assessment of optimal hydrocortisone replacement therapy. Clin Endocrinol 1997; 46: 263–8
Peacey SR GC, Robinson AM, Price A, et al. Glucocorticoid replacement therapy: are patients over treated and does it matter? Clin Endocrinol 1997; 46: 255–61
Oelkers W, Diederich S, Bähr V. Diagnosis and therapy surveillance in Addison’s disease: rapid adrenocorticotropin (ACTH) test and measurement of plasma ACTH, renin activity, and aldosterone. J Clin Endocrinol Metab 1992; 75: 259–64
Peacey SR, Guo CY, Eastell R, et al. Optimization of glucocorticoid replacement therapy: the long-term effect on bone mineral density. Clin Endocrinol 1999; 50: 815–9
Winqvist O, Gebre-Mehdin G, Gustafsson J, et al. Identification of the main adrenal autoantigens in patients with adrenal insufficiency and associated ovarian failure. J Clin Endocrinol Metab 1995; 80: 1717–23
Arlt W, Callies F, Vlijmen JCv, et al. Dehydroepiandosterone replacement in women with adrenal insufficiency. N Engl J Med 1999; 341: 1013–20
Acknowledgements
This work was supported by the Swedish Medical Research Council, Torsten and Ragnar Söderberg Foundation and the Swedish Diabetes Research Foundation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Winqvist, O., Rorsman, F. & Kämpe, O. Autoimmune Adrenal Insufficiency. BioDrugs 13, 107–114 (2000). https://doi.org/10.2165/00063030-200013020-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00063030-200013020-00004